LFCR Valuation

Lifecore Biomedical Inc

Add to Watchlist

Advanced Chart

7.110

-0.11(-1.524%)1D

Overview
Forecast
Valuation
Earnings

LFCR Relative Valuation

LFCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LFCR is overvalued; if below, it's undervalued.

Historical Valuation

Lifecore Biomedical Inc (LFCR) is now in the Fair zone, suggesting that its current forward PS ratio of 2.11 is considered Fairly compared with the five-year average of -60.77. The fair price of Lifecore Biomedical Inc (LFCR) is between 4.58 to 7.47 according to relative valuation methord.

Relative Value

Fair Zone

4.58-7.47

Current Price：7.22

Fair

-15.70

Trailing

Forward

20.93

EV/EBITDA

Lifecore Biomedical Inc. (LFCR) has a current EV/EBITDA of 20.93. The 5-year average EV/EBITDA is 23.05. The thresholds are as follows: Strongly Undervalued below -14.39, Undervalued between -14.39 and 4.33, Fairly Valued between 41.77 and 4.33, Overvalued between 41.77 and 60.50, and Strongly Overvalued above 60.50. The current Forward EV/EBITDA of 20.93 falls within the Historic Trend Line -Fairly Valued range.

-87.51

EV/EBIT

Lifecore Biomedical Inc. (LFCR) has a current EV/EBIT of -87.51. The 5-year average EV/EBIT is 6.84. The thresholds are as follows: Strongly Undervalued below -152.83, Undervalued between -152.83 and -72.99, Fairly Valued between 86.68 and -72.99, Overvalued between 86.68 and 166.51, and Strongly Overvalued above 166.51. The current Forward EV/EBIT of -87.51 falls within the Undervalued range.

2.05

Lifecore Biomedical Inc. (LFCR) has a current PS of 2.05. The 5-year average PS is 1.53. The thresholds are as follows: Strongly Undervalued below 0.47, Undervalued between 0.47 and 1.00, Fairly Valued between 2.05 and 1.00, Overvalued between 2.05 and 2.58, and Strongly Overvalued above 2.58. The current Forward PS of 2.05 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Lifecore Biomedical Inc. (LFCR) has a current P/OCF of 0.00. The 5-year average P/OCF is 1.11. The thresholds are as follows: Strongly Undervalued below -11.03, Undervalued between -11.03 and -4.96, Fairly Valued between 7.19 and -4.96, Overvalued between 7.19 and 13.26, and Strongly Overvalued above 13.26. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

54.56

P/FCF

Lifecore Biomedical Inc. (LFCR) has a current P/FCF of 54.56. The 5-year average P/FCF is 1.62. The thresholds are as follows: Strongly Undervalued below -78.48, Undervalued between -78.48 and -38.43, Fairly Valued between 41.67 and -38.43, Overvalued between 41.67 and 81.72, and Strongly Overvalued above 81.72. The current Forward P/FCF of 54.56 falls within the Overvalued range.

Lifecore Biomedical Inc (LFCR) has a current Price-to-Book (P/B) ratio of 121.76. Compared to its 3-year average P/B ratio of 16.33 , the current P/B ratio is approximately 645.70% higher. Relative to its 5-year average P/B ratio of 10.47, the current P/B ratio is about 1063.36% higher. Lifecore Biomedical Inc (LFCR) has a Forward Free Cash Flow (FCF) yield of approximately -3.95%. Compared to its 3-year average FCF yield of -15.23%, the current FCF yield is approximately -74.06% lower. Relative to its 5-year average FCF yield of -12.55% , the current FCF yield is about -68.53% lower.

119.93

P/B

Median3y

16.33

Median5y

10.47

-4.07

FCF Yield

Median3y

-15.23

Median5y

-12.55

Competitors Valuation Multiple

The average P/S ratio for LFCR's competitors is 2.31, providing a benchmark for relative valuation. Lifecore Biomedical Inc Corp (LFCR) exhibits a P/S ratio of 2.05, which is -11.23% above the industry average. Given its robust revenue growth of -1.54%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LFCR.O

Lifecore Biomedical Inc

Vanda Pharmaceuticals Inc

scPharmaceuticals Inc

Esperion Therapeutics Inc

0.79

-52.81%

279.46M

Performance Decomposition

Market capitalization of LFCR increased by 12.32% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.54 to -4.84.

The secondary factor is the Revenue Growth, contributed -1.54%to the performance.

Overall, the performance of LFCR in the past 1 year is driven by P/E Change. Which is more unsustainable.

-1.54%

35.70M → 35.15M

Revenue Growth

-201.45%

41.41 → -42.01

Margin Expansion

215.31%

-1.54 → -4.84

P/E Change

12.32%